Syros Pharmaceuticals (SYRS) to Release Earnings on Thursday

Syros Pharmaceuticals (NASDAQ:SYRS) is set to announce its earnings results before the market opens on Thursday, October 31st. Analysts expect the company to announce earnings of ($0.67) per share for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.

Syros Pharmaceuticals (NASDAQ:SYRS) last posted its quarterly earnings data on Wednesday, July 31st. The company reported ($0.70) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.79) by $0.09. On average, analysts expect Syros Pharmaceuticals to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Syros Pharmaceuticals Stock Performance

Syros Pharmaceuticals stock opened at $2.11 on Tuesday. The stock has a fifty day moving average price of $1.86 and a 200 day moving average price of $4.03. Syros Pharmaceuticals has a 52 week low of $1.43 and a 52 week high of $8.17. The firm has a market capitalization of $56.40 million, a P/E ratio of -0.42 and a beta of 1.59. The company has a current ratio of 3.46, a quick ratio of 3.46 and a debt-to-equity ratio of 1.97.

Wall Street Analysts Forecast Growth

SYRS has been the topic of several recent analyst reports. StockNews.com upgraded shares of Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, October 15th. HC Wainwright lowered their price objective on shares of Syros Pharmaceuticals from $15.00 to $6.00 and set a “buy” rating for the company in a research note on Tuesday, August 13th. Piper Sandler reaffirmed an “overweight” rating and issued a $5.00 target price (down from $13.00) on shares of Syros Pharmaceuticals in a research report on Tuesday, August 13th. Finally, JMP Securities dropped their target price on shares of Syros Pharmaceuticals from $12.00 to $4.00 and set a “market outperform” rating for the company in a research report on Tuesday, August 13th.

Insider Activity at Syros Pharmaceuticals

In related news, CEO Conley Chee acquired 50,000 shares of Syros Pharmaceuticals stock in a transaction on Tuesday, September 10th. The shares were bought at an average price of $1.51 per share, for a total transaction of $75,500.00. Following the completion of the purchase, the chief executive officer now directly owns 72,504 shares in the company, valued at $109,481.04. This trade represents a 200.00 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, CEO Conley Chee acquired 50,000 shares of the stock in a transaction on Tuesday, September 10th. The stock was bought at an average price of $1.51 per share, with a total value of $75,500.00. Following the completion of the transaction, the chief executive officer now directly owns 72,504 shares of the company’s stock, valued at $109,481.04. The trade was a 200.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO Jason Haas bought 35,363 shares of Syros Pharmaceuticals stock in a transaction dated Tuesday, September 10th. The shares were purchased at an average cost of $1.55 per share, for a total transaction of $54,812.65. Following the completion of the transaction, the chief financial officer now owns 59,915 shares of the company’s stock, valued at approximately $92,868.25. This represents a 100.00 % increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders purchased 130,707 shares of company stock worth $206,491. Corporate insiders own 12.26% of the company’s stock.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.